KR102651290B1 - 항-il-5 항체 - Google Patents

항-il-5 항체 Download PDF

Info

Publication number
KR102651290B1
KR102651290B1 KR1020197021088A KR20197021088A KR102651290B1 KR 102651290 B1 KR102651290 B1 KR 102651290B1 KR 1020197021088 A KR1020197021088 A KR 1020197021088A KR 20197021088 A KR20197021088 A KR 20197021088A KR 102651290 B1 KR102651290 B1 KR 102651290B1
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
ser
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197021088A
Other languages
English (en)
Korean (ko)
Other versions
KR20190126769A (ko
Inventor
마크 터렌스 리다먼트
안토니 도일리
아담 클라크
데이빗 죠스 시몬 레인
브리짓 앤 쿡세이
Original Assignee
세파론 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세파론 엘엘씨 filed Critical 세파론 엘엘씨
Publication of KR20190126769A publication Critical patent/KR20190126769A/ko
Application granted granted Critical
Publication of KR102651290B1 publication Critical patent/KR102651290B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197021088A 2016-12-23 2017-12-20 항-il-5 항체 Active KR102651290B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438502P 2016-12-23 2016-12-23
US62/438,502 2016-12-23
PCT/US2017/067475 WO2018119016A1 (en) 2016-12-23 2017-12-20 Anti-il-5 antibodies

Publications (2)

Publication Number Publication Date
KR20190126769A KR20190126769A (ko) 2019-11-12
KR102651290B1 true KR102651290B1 (ko) 2024-03-25

Family

ID=60972458

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021088A Active KR102651290B1 (ko) 2016-12-23 2017-12-20 항-il-5 항체

Country Status (20)

Country Link
US (2) US11111292B2 (cg-RX-API-DMAC7.html)
EP (1) EP3559030B1 (cg-RX-API-DMAC7.html)
JP (1) JP7060906B2 (cg-RX-API-DMAC7.html)
KR (1) KR102651290B1 (cg-RX-API-DMAC7.html)
CN (1) CN110267986B (cg-RX-API-DMAC7.html)
AR (1) AR110564A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017379853B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019012929A2 (cg-RX-API-DMAC7.html)
CA (1) CA3048186A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001730A1 (cg-RX-API-DMAC7.html)
EA (1) EA201991552A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984636T3 (cg-RX-API-DMAC7.html)
IL (1) IL267271B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019007642A (cg-RX-API-DMAC7.html)
NZ (1) NZ754606A (cg-RX-API-DMAC7.html)
PE (1) PE20191662A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501452A1 (cg-RX-API-DMAC7.html)
RU (1) RU2758008C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018119016A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201904097B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991552A1 (ru) * 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела
SMT202600240T1 (it) 2017-05-26 2026-07-16 Glaxosmithkline Ip Dev Ltd Composizioni biofarmaceutiche e metodi correlati
CN113366016B (zh) * 2018-12-12 2022-12-16 上海开拓者生物医药有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
JP7641908B2 (ja) 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
CN112745389B (zh) * 2019-10-29 2022-11-25 瑞阳(苏州)生物科技有限公司 结合人il-5的单克隆抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003085089A2 (en) 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
KR100511544B1 (ko) * 1994-12-23 2005-08-31 스미스클라인 비참 코포레이션 Ｉｌ－5 매개된 질환의 치료에 유용한 재조합 ｉｌ－5길항제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
EP3365369A1 (en) * 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
EA201991552A1 (ru) * 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100511544B1 (ko) * 1994-12-23 2005-08-31 스미스클라인 비참 코포레이션 Ｉｌ－5 매개된 질환의 치료에 유용한 재조합 ｉｌ－5길항제
WO2003085089A2 (en) 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Also Published As

Publication number Publication date
US20210355205A1 (en) 2021-11-18
EP3559030A1 (en) 2019-10-30
MX2019007642A (es) 2019-09-09
ZA201904097B (en) 2023-12-20
WO2018119016A1 (en) 2018-06-28
PE20191662A1 (es) 2019-11-11
EP3559030B1 (en) 2024-04-03
IL267271B2 (en) 2025-10-01
JP2020513761A (ja) 2020-05-21
AR110564A1 (es) 2019-04-10
CN110267986B (zh) 2023-05-09
JP7060906B2 (ja) 2022-04-27
AU2017379853A1 (en) 2019-07-04
ES2984636T3 (es) 2024-10-30
IL267271A (en) 2019-08-29
US20180186873A1 (en) 2018-07-05
RU2019123112A3 (cg-RX-API-DMAC7.html) 2021-04-05
RU2019123112A (ru) 2021-01-26
US12577298B2 (en) 2026-03-17
NZ754606A (en) 2023-06-30
EP3559030C0 (en) 2024-04-03
US11111292B2 (en) 2021-09-07
PH12019501452A1 (en) 2020-06-15
EA201991552A1 (ru) 2020-01-09
AU2017379853B2 (en) 2025-02-06
CN110267986A (zh) 2019-09-20
KR20190126769A (ko) 2019-11-12
BR112019012929A2 (pt) 2019-12-10
CA3048186A1 (en) 2018-06-28
IL267271B1 (en) 2025-06-01
CL2019001730A1 (es) 2019-09-27
RU2758008C2 (ru) 2021-10-25

Similar Documents

Publication Publication Date Title
RU2758008C2 (ru) Анти-il-5 антитела
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
US20250034248A1 (en) Monoclonal antibodies against human tim-3
RU2771384C2 (ru) Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение
JP2019516362A (ja) 抗ｉｌ−３３抗体、その組成物、方法および使用
JP7726534B2 (ja) 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
MX2008014804A (es) Anticuerpos de afinidad elevada a receptor de il-6 humano.
CN121226555A (zh) 抗cMET抗体
AU2021358662A9 (en) CD1a ANTIBODIES AND USES THEREOF
CN121226557A (zh) 抗cMET抗体
CN121270705A (zh) 抗cMET抗体
JP2023551981A (ja) 多重特異性抗体及び抗体の組み合わせ
KR20220117267A (ko) Tgf-베타-rii 결합 단백질
RU2824390C2 (ru) Фармацевтическая композиция, содержащая антитело против il-5, и ее применение
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
EA042576B1 (ru) Анти-il-5 антитела
HK40015055B (en) Anti-il-5 antibodies
HK40015055A (en) Anti-il-5 antibodies
AU2024372112A1 (en) Fibroblast targeting molecules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201216

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221125

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230508

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221125

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230508

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230119

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201216

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230731

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20240207

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230927

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230717

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230508

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230119

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201216

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240321

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240321

End annual number: 3

Start annual number: 1

PG1601 Publication of registration